Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
28.41 USD
-1.22%
Market Closed
Updated:
May 4, 2024
Royalty Pharma PLC
Revenue
|
Royalty Pharma PLC
Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
Revenue
$2.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$81.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$45.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$58.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$61.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$34.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
Royalty Pharma PLC
Revenue Breakdown
Breakdown by Geography
Royalty Pharma PLC
Royalty Pharma PLC
Not Available
Breakdown by Segments
Royalty Pharma PLC
Royalty Pharma PLC
|
Total Revenue:
2.4B
USD
|
|
Income From Financial Royalty Assets:
2.2B
USD
|
|
Other Royalty Income:
156m
USD
|
|
Revenue From Intangible Royalty Assets:
835k
USD
|
See Also
What is Royalty Pharma PLC's Revenue?
Revenue
2.4B
USD
2.4B
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Revenue amounts to 2.4B USD.
What is Royalty Pharma PLC's Revenue growth rate?
Revenue CAGR 5Y
6%
6%
Over the last year, the Revenue growth was 5%. The average annual Revenue growth rates for Royalty Pharma PLC have been 4% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
